Your search found 70 Results
Guideline: Managing possible serious bacterial infection in young infants when referral is not feasible.
Geneva, Switzerland, WHO, 2015.  p.This guideline, developed by a panel of international experts and informed by a thorough review of existing evidence, contains a number of recommendations on the use of antibiotics for neonates (0–28 days old) and young infants (0–59 days old) with PSBI in order to reduce young infant mortality rates. The guideline is intended for use in resource-limited settings in situations when families do not accept or cannot access referral care. The goal of the guideline is to provide clinical guidance on the simplest antibiotic regimens that are both safe and effective for outpatient treatment of clinical severe infections and fast breathing (pneumonia) in children 0–59 days old. In addition, the guideline seeks to provide programmatic guidance on the role of CHWs and home visits in identifying signs of serious infections in neonates and young infants.
Bulletin of the World Health Organization. 2011 May 1; 89(5):390-2.This article focuses on antimicrobial resistance, which challenges the control of infectious diseases, jeopardizes progress on health outcomes by increasing morbidity and mortality, and imposes huge costs on societies. It discusses several aspects related to antimicrobial resistance including: the lack of commitment and data, un-assured drug quality, poor prevention and control of infections, and weaker research efforts. It concludes by outlining the World Health Organization's policy package to combat antimicrobial resistance, which reframes the critical actions to be taken by governments to stimulate change by all stakeholders.
WHO guidelines for antimicrobial treatment in children admitted to hospital in an area of intense Plasmodium falciparum transmission: prospective study.
BMJ. British Medical Journal. 2010; 340:c1350.OBJECTIVES: To assess the performance of WHO's "Guidelines for care at the first-referral level in developing countries" in an area of intense malaria transmission and identify bacterial infections in children with and without malaria. DESIGN: Prospective study. SETTING: District hospital in Muheza, northeast Tanzania. PARTICIPANTS: Children aged 2 months to 13 years admitted to hospital for febrile illness. MAIN OUTCOME MEASURES: Sensitivity and specificity of WHO guidelines in diagnosing invasive bacterial disease; susceptibility of isolated organisms to recommended antimicrobials. RESULTS: Over one year, 3639 children were enrolled and 184 (5.1%) died; 2195 (60.3%) were blood slide positive for Plasmodium falciparum, 341 (9.4%) had invasive bacterial disease, and 142 (3.9%) were seropositive for HIV. The prevalence of invasive bacterial disease was lower in slide positive children (100/2195, 4.6%) than in slide negative children (241/1444, 16.7%). Non-typhi Salmonella was the most frequently isolated organism (52/100 (52%) of organisms in slide positive children and 108/241 (45%) in slide negative children). Mortality among children with invasive bacterial disease was significantly higher (58/341, 17%) than in children without invasive bacterial disease (126/3298, 3.8%) (P<0.001), and this was true regardless of the presence of P falciparum parasitaemia. The sensitivity and specificity of WHO criteria in identifying invasive bacterial disease in slide positive children were 60.0% (95% confidence interval 58.0% to 62.1%) and 53.5% (51.4% to 55.6%), compared with 70.5% (68.2% to 72.9%) and 48.1% (45.6% to 50.7%) in slide negative children. In children with WHO criteria for invasive bacterial disease, only 99/211(47%) of isolated organisms were susceptible to the first recommended antimicrobial agent. CONCLUSIONS: In an area exposed to high transmission of malaria, current WHO guidelines failed to identify almost a third of children with invasive bacterial disease, and more than half of the organisms isolated were not susceptible to currently recommended antimicrobials. Improved diagnosis and treatment of invasive bacterial disease are needed to reduce childhood mortality.
Evidence behind the WHO guidelines: hospital care for children: what is the aetiology of pneumonia in HIV-infected children in developing countries?
Journal of Tropical Pediatrics. 2009 Aug; 55(4):219-24.This clinical review discusses the most common cause of pneumonia in HIV-infected children--bacterial pathogens and includes recommendations for the management of pneumonia in HIV-infected children from World Health Organization (WHO).
Journal of Tropical Pediatrics. 2006 Feb; 52(1):46-48.The World Health Organization has produced guidelines for the management of common illnesses in hospitals with limited resources. This series reviews the scientific evidence behind WHO's recommendations. The WHO guidelines, and more reviews are available at http://www.who.int/child-adolescenthealth/ publications/CHILD_HEALTH/PB.htm. This review addresses the question: ''What are the most appropriate empirical first-line antibiotics for children with septicaemia?'' The WHO Pocketbook of Hospital Care for Children states: Antibiotic therapy - Where blood cultures are available, obtain blood cultures before starting antibiotics - Give ampicillin (or penicillin) and gentamicin - Give cloxacillin (if available) instead of penicillin if extensive skin pustules or abscesses as these might be signs of Staphylococcus infection. (excerpt)
Antibiotic treatment of community acquired pneumonia in well-nourished young Nigerian children [letter]
Journal of Tropical Pediatrics. 2005 Oct; 51(5):319-320.Worldwide, Streptococcus pneumoniae and Haemophilus influenzae are reported to be responsible for about 57 per cent of community-acquired pneumonia in children, whereas, Staphylococcus aureus contributes only 14 per cent. Based on this, the WHO has recommended the use of crystalline penicillin and amoxycillin given sequentially for the treatment of severe community-acquired pneumonia. However, this appears not to have been fully accepted in Nigeria, presumably because most aetiological studies of pneumonia in the country have indicated that S. aureus and Klebsiella spp. predominate. However, those in whom S. aureus and Klebsiella spp were isolated were not all cases of community-acquired pneumonia; while a substantial number were malnourished. Therefore, we carried out a retrospective study of the use of the sequentially administered intravenous (i.v.) crystalline penicillin and oral amoxycillin, or i.v. flucloxacillin given simultaneously with intramuscular (i.m.) gentamicin, in the treatment of severe community-acquired pneumonia in well-nourished under-five-year olds in a hospital setting. (excerpt)
Generic protocol to estimate the burden of Shigella diarrhoea and dysenteric mortality. Field test version, May 1999.
Geneva, Switzerland, World Health Organization [WHO], Department of Vaccines and Biologicals, 1999. 37 p. (WHO/V&B/99.26)The WHO Department of Vaccines and Biologicals (V&B) has an increasing interest in vaccines against Shigella, and several candidate vaccines are being tested in clinical trials. The promise of having a new generation of vaccines available in the relatively near future emphasizes the need to understand the disease burden and the epidemiology of Shigella infection in developing countries. The V&B Steering Committee on Epidemiology and Field Research and the V&B Steering Committee on Diarrhoeal Disease Vaccines jointly identified the need for a practical method for immunization programme managers and clinical epidemiologists to assess the local disease burden due to Shigella. At the request of these Steering Committees, this generic protocol was prepared by staff at the U.S National Institute of Child Health and Human Development, the University of Maryland, and the U.S. Centers for Disease Control and Prevention. This protocol provides a general outline for a study and describes the main procedures involved. However, it will need to be adapted to the local setting, and details of field work and operational procedures should be added by local investigators with experience in conducting field studies of diarrhoeal diseases. WHO provides this protocol free-of-charge. In return, WHO would appreciate being informed about studies conducted using this protocol. This WHO document should be referenced in any publication resulting from its use. Comments or suggestions for improving this generic protocol are welcome and should be sent to the Department of Vaccines and Biologicals, WHO, 1211 Geneva 27, Switzerland. (excerpt)
Antimicrobial and support therapy for bacterial meningitis in children. Report of the meeting of 18- 20 June 1997, Geneva, Switzerland.
Geneva, Switzerland, WHO, Division of Emerging and Other Communicable Diseases Surveillance and Control, 1998.  p. (WHO/CHD/98.6; WHO/EMC/BAC/98.2)WHO and UNICEF have developed an integrated approach to address the major life-threatening illnesses of children known as Integrated Management of Childhood Illness (IMCI). Lessons learned from disease-specific programmes have been applied to promote co-ordination and integration of the activities to improve the prevention and management of childhood illness. Apart from five major killer diseases of children under five years (acute respiratory infections - mostly pneumonia, diarrhoea, measles, malaria and malnutrition) bacterial meningitis is an important cause of childhood morbidity and mortality. (excerpt)
CMAJ: Canadian Medical Association Journal. 2004 Apr 13; 170(8):1225.Trachoma is a chronic keratoconjunctivitis caused by repeated infection with the ocular serovars A, B, Ba and C of Chlamydia trachomatis. The name, derived from the Greek word for “rough,” describes the appearance of the lymphoid follicles apparent with trachomatous inflammation when the upper eyelid is everted and the upper tarsal conjunctiva inspected. A single episode of C. trachomatis ocular infection produces a self-limiting mucopurulent conjunctivitis. Repeated infections lead to conjunctival scarring and distortion of the lid margin, which causes the eyelashes to turn inward (entropion) and repeatedly rub against the cornea (trichiasis). The catastrophic outcome is corneal opacification and, ultimately, blindness. Trachoma is second only to cataracts as a cause of blindness and accounts for about 15% of cases of blindness in the world. In 1997 the World Health Organization (WHO) estimated that 146 million people were actively infected, more than 10 million had trichiasis, and about 6 million were blind from corneal scarring. Active disease is most often seen in children, and women more often than men experience the visual loss that results from chronic, untreated disease, probably because of their greater direct contact with children. (excerpt)
[Geneva, Switzerland], WHO, 1994. , 17 p. (WHO/CDD/94.49)The clinical diagnosis of bloody diarrhea refers to any diarrheal episode in which the loose or watery stools contain visible red blood. This does not include episodes in which blood is present in streaks on the surface of formed stool, is detected only by microscopic examination or biochemical tests, or in which stools are black due to the presence of digested blood. The health practitioner may diagnose the presence of bloody diarrhea in a child by either asking the mother whether the child's stool contains red blood or by looking at the stool, but the former approach is usually more efficient than waiting for the child to pass a stool and as equally sensitive and precise. All infants and children with bloody diarrhea should be treated promptly with an antimicrobial effective against Shigella. Such antimicrobials include ampicillin, TMP-SMX (cotrimoxazole), nalidixic acid, pivvmecillinam, newer quinolones, and ceftriaxone. Dehydration when detected in children with bloody diarrhea should be treated at the health facility. Children with bloody diarrhea and signs of dehydration are at increased risk of complications and should be re-evaluated two days after treatment. The caretakers of all children should be encouraged to offer increased amounts of suitable fluids at home. Moreover, the continued provision of nutritious food is important for all children with dysentery, even though they may have to be coaxed to eat. Appetite usually improves after 1-2 days of effective antibiotic therapy. Frequent small meals with familiar foods are usually better tolerated than a few large meals. Furthermore, mothers should be advised to breastfeed as often and as long as their children want, while children convalescing from dysentery should be given an extra meal each day for at least two weeks. Severely malnourished children with bloody diarrhea are at very high risk of complications and should be referred immediately to hospital after starting treatment for shigellosis.
Geneva, Switzerland, WHO, Division of Family Health, Programme of Maternal and Child Health and Family Planning, 1991 Dec. , 122 p. (WHO/MCH/91.10)This WHO consultation on maternal and perinatal infections reviews the epidemiology of these infections, examines the effectiveness of known intervention strategies to prevent and treat these infections, notes gaps in current knowledge, and develops recommendations for implementation of appropriate control strategies. The report is geared toward maternal and child health professionals in developing countries where maternal and perinatal infections cause considerable morbidity and death. These countries have limited resources for health care (e.g., US $5-10/person), largely due to the worsening economic situation. The report centers on the feasibility, effectiveness, and cost of interventions to prevent, treat, and control the infections. It has summary cost-effective analyses of maternal and perinatal infections and proposed interventions using 3 different hypothetical country situations to help policymakers decide on priorities and policies on prevention, treatment, and control of these infections. The report dedicates a chapter to each infection (syphilis, neonatal tetanus, malaria, hepatitis, HIV infections, chlamydial infections, herpes simplex infection, Group B Streptococcal infections, and maternal genital infection causing premature birth and low birth weight). Each chapter addresses their clinical and public health significance; prevalence in pregnant women and transmission from mother to fetus/infant; clinical effects; prevention, treatment, and control; and cost effectiveness and feasibility of various interventions. Based on public health importance, feasibility, and affordability, the consultants agreed that national and international programs should place the highest priority on these perinatal infections: gonococcal ophthalmia neonatorum, maternal and congenital syphilis, neonatal tetanus, hepatitis B, and maternal puerperal infections.
Cholera: ancient scourge on the rise. WHO announces global plan for cholera control. (25 April 1991).
WHO FEATURES. 1991 Apr; (154):1-3.Vibrio cholerae spreads quickly via contaminated water and food, especially in areas with a poor health and sanitation infrastructure. Its enterotoxin induces vomiting and huge amounts of watery diarrhea leading to severe dehydration. 80-90% of cholera victims during an epidemic can use oral rehydration salts. A cholera epidemic is now spreading through Latin America threatening 90-120 million people (started in January 1991), particularly those in urban slums and rural/mountainous areas. As of mid April 1991, there were more than 177,000 new reported cases in 12 countries and 78% of these cases and more than 1200 deaths were limited to 5 countries: Brazil, Chile, Colombia, Ecuador, and Peru, WHO's Global Cholera Control Task Force coordinates global cholera control efforts to prevent deaths in the short term and to support infrastructure development in the long term. Its members are specialists in disease surveillance, case management, water and sanitation, food safety, emergency intervention, and information and education. WHO's Director General is asking for the support of the international community in cholera control activities. These activities' costs are considerable. For example, Peru needs about US$ 60 million in 1992 to fulfill only the most immediate demands of rehabilitation and reconstruction of the infrastructure. Costs of infrastructure capital throughout Latin America is almost US$ 5 thousand million/year over the next 10 years. It is indeed an effective infrastructure which ultimately prevents cholera. Cholera is evidence of inadequate development, so to fight it, we must also fight underdevelopment and poverty.
BULLETIN OF THE WORLD HEALTH ORGANIZATION. 1991; 69(6):667-76.WHO's Programme for Control of Diarrheal Diseases (CDD) promoted and supported research the purpose of which is to develop and evaluate vaccines against diarrheal diseases, but it focused on diarrhea control. In 1991, the WHO/UNDP Programme for Vaccine Development (PVD) began coordinating diarrheal disease vaccine research, yet CDD remained actively involved in vaccine trials. In March 1991, CDD and PVD cosponsored a meeting to specify new research priorities toward vaccines against rotaviruses, Shigella, cholera, and enterotoxigenic Escherichia coli (ETEC) infections. Synopses of clinical trials on vaccines that have undergone clinical trials are presented. Different methods of developing vaccines against rotavirus included heterologous rotavirus adapted to tissue cultures, incorporating the VP7 surface protein of human rotaviruses into an animal rotavirus, and naturally attenuated. Live oral vaccines, different ways to immunize with oral encapsulated antigens, and a gycoconjugate approach comprised the Shigella vaccine research. There were many candidate Shigella vaccines which the meeting participants found to be promising and challenging. Cholera vaccines included killed and live oral vaccines. The results of a large field trial of cholera vaccines (killed whole cell/B subunit and whole cell culture) in Bangladesh revealed marked improvements over injected vaccines. A study of children in Indonesia showed promise for strain CVD-103HgR as a 1 dose, live oral vaccine against cholera. Adult volunteers who received milk immunoglobulin concentrate with antibodies against several colonization factor fimbriae (LT and O antigens) and then challenged experimentally with ETEC were 100% protected. WHO emphasized the need to develop both living and nonliving oral ETEC vaccines which will grant broad spectrum immunity to young children. Specific recommendations follow each section on the various vaccines and general recommendations are included.
Oxford, England, Oxford University Press, 1990. xix, 136 p.The Commission on Health Research for Development is an independent international consortium formed in 1987 to improve the health of people in developing countries by the power of research. This book is the result of 2 years of effort: 19 commissioned papers, 8 expert meetings, 8 regional workshops, case studies of health research activities in 10 developing countries and hundreds of individual discussions. A unique global survey examined financing, locations and promotion of health research. The focus of all this work was the influence of health on development. This book has 3 sections: a review of global health inequities and why health research is needed; findings of country surveys, health research financing, selection of topics and promotion; conclusions and recommendations. Some research priorities are contraception and reproductive health, behavioral health in developing countries, applied research on essential drugs, vitamin A deficiency, substance abuse, tuberculosis. The main recommendations are: that all countries begin essential national health research (ENHR), with international partnership; that larger and sustained international funding for research be mobilized; and that larger and sustained international funding for research be mobilized; and that international mechanisms for monitoring progress be established. The book is full of graphs and contains footnotes, a complete bibliography and an index.
Report of the European Region on Immunization Activities. (Global Advisory Group EPI, Alexandria, October 1984). WHO/Expanded Immunization Programme and the European Immunization Targets in the Framework of HFA 2000.
[Unpublished] 1984. Presented at the EPI Global Advisory Group Meeting, Alexandria, Egypt, 21-25 October 1984. 3 p. (EPI/GAG/84/WP.4)Current reported levels of morbidity and mortality from measles, poliomyelitis, diphtheria, tetanus, and tuberculosis in most countries in the European Region are at or near record low levels. However, several factors threaten successful achievement of the Expanded Program on Immunization (EPI) goal of making immunization services available to all the world's children by the year 2000, including changes in public attitudes as diseases pose less of a visible threat, declining acceptance rates for certain immunizations, variations in vaccines included in the EPI, and incomplete information on the incidence of diseases preventable by immunization and on vaccination coverage rates. To launch a more coordinated approach to the EPI goals, a 2nd Conference on Immunization Policies in Europe is scheduled to be held in Czechoslovakia. Its objectives are: 1) to review and analyze the current situation, including achievements and gaps, in immunization programs in individual countries and the European Region as a whole; 2) to determine the necessary actions to eliminate indigenous measles, poliomyelitis, neonatal tetanus, congenital rubella, and diphtheria; 3) to consider appropriate policies regarding the control by immunization of other diseases of public health importance; 4) to strengthen existing or establish additional systems for effective monitoring and surveillance; 5) to formulate actions necessary to improve national vaccine programs in order to achieve national and regional targets; 6) to reinforce the commitment of Member Countries to the goals and activities of the EPI; and 7) to define appropriate activities for the Regional Office for Europe of the World Health Organization to achieve coordinated action.
Report of the Expanded Programme on Immunization Global Advisory Group Meeting, 20-23 October 1980, Geneva.
[Unpublished] 1980. 39 p. (EPI/GEN/80/1)This report of the Expanded Program on Immunization (EPI) Global Advisory Group Meeting, held during October 1980 in Geneva, Switzerland, presents conclusions and recommendations, global and regional overviews, working group discussions, and outlines global advisory group activities for 1981. In terms of global strategies, the EPI confronts dual challenges: to reduce morbidity and mortality by providing immunizations for all children of the world by 1990; and to develop immunization services in consonance with other health services, particularly those directed towards mothers and children, so they can mutually strengthen the approach of primary health care. Increased resources are needed to support the expansion of immunization services and to establish them as permanent elements of the health care system. The Global Advisory Group affirms the importance of setting quantified targets as a basic principle of management and endorses the principle of setting targets for the reduction of the EPI diseases at national, regional, and global levels. The primary focus for the World Health Organization (WHO) in promoting the EPI continues to be the support to national program implementation in all its aspects. The Group reviewed current EPI immunization schedules and policies and concurs in the following: for measles, for most developing countries, the available data support the current recommendations of administering a single dose of vaccine to children as early as possible after the child reaches the age of 9 months; for DPT, children in the 1st year of life should receive a series of 3 DPT doses administered at intervals of at least 1 month; for tetanus toxoid, the control of neonatal and puerperal tetanus by immunizing women of childbearing age, particularly pregnant women, is endorsed; for poliomyelitis, the Group endorses the "Outline for WHO's Research on Poliomyelitis, Polioviruses and Poliomyelitis Vaccines" prepared by the WHO Working Group convened in October 1980, i.e., for oral (live) vaccines, a 3-dose schedule, administered simultaneously with DPT vaccine, is recommended again; and for BCG concurred with the Advisory Committee on Medical Research conclusion that the use of BCG as an anti-tuberculosis measure within the EPI should be continued as at present. The implementation of programs at the national level remains the foremost priority for the EPI. National commitment, evidenced in part by the designation of a national manager, the establishment of realistic targets, and the allocation of adequate resources, is essential if programs are to succeed.
WORLD HEALTH ORGANIZATION TECHNICAL REPORT SERIES. 1980; (651):1-19.This document reports the discussions of a Scientific Group on Vaccination Against Tuberculosis, cosponsored by the Indian Council of Medical Research and the World Health Organization (WHO), that met in 1980. The objectives of the meeting were to review research on Bacillus Calmete-Guerin (BCG) vaccination, assess the present state of knowledge, and determine how to advance this knowledge. Particular emphasis is placed in this document on the trial of BCG vaccines in South India. In this trial, the tuberculin sensitivity induced by BCG vaccination was highly satisfactory at 2 1/2 months but had waned sharply by 2 1/2 years and the 7 1/2-year follow up revealed a high incidence of tuberculous infection in the study population. It is suggested that the protective effect of BCG may depend on epidemiologic, environmental, and immunologic factors affecting both the host and the infective agent. Studies to test certain hypotheses (e.g., the immune response of the study population was unusual, the vaccines were inadequate, the south Indian variant of M tuberculosis acted as an attenuating immunizing agent, and mycobacteria other than M tuberculosis may have partially immunized the study population) are recommended. A detailed analysis should be made when results from the 10-year follow up of the south Indian study population are available.
WORLD HEALTH ORGANIZATION TECHNICAL REPORT SERIES. 1974; (552):1-40.This document represents the work of a World Health Organization (WHO) Expert Committee on Tuberculosis, which met in Geneva in 1973. Chapters in this volume focus on epidemiology, Bacillus Calmette-Guerin (BCG) vaccination, case finding and treatment, national tuberculosis programs, research, WHO activities in this field, and the activities of the International Union against Tuberculosis and voluntary groups. The Committee emphasized that tuberculosis still ranks among the world's major health problems, particularly in developing countries. Even in many developed countries, tuberculosis and its sequelae are a more important cause of death than all the other notifiable infectious diseases combined. The previous WHO report, issued in 1964, set forth the concept of a comprehensive tuberculosis control program on a national scale. The implementation of this approach has encountered many problems, including deficiencies in the health infrastructure of many countries (shortages of financial, material, and physical resources and a lack of trained manpower) and resistance to change. However, many countries have instituted comprehensive programs and tuberculosis control has become a widely applied community health activity. A priority will be control of pulmonary tuberculosis. The Committee stressed that national programs must be countrywide, permanent, adapted to the expressed demands of the population, and integrated in the community health structure. Steps involved in setting up such programs include planning and programming, selection of technical policies, implementation, and evaluation. Research priority areas identified by the Committee include epidemiology, bacteriology and immunology, immunization, chemotherpy, the systems analysis approach to tuberculosis control, and training methods and instructional materials.
[Unpublished] 1986. 80 p. (WHO/CDD/84.17)This listing of research projects funded since 1980 by the Diarrheal Diseases Control Program of the WHO is arranged by broad priority area and scientific working group. Project title, investigator, and budget allocation for each are listed. Scientific working groups which are included are: bacterial enteric infections, parasitic diarrheas, viral diarrheas, drug development and management of acute diarrheas, global/global groups, global/regional groups, and research strengthening activities. Projects are also classified according to geographic area: African region, American region, Eastern Meditterranean region, European region, Southeast Asia region, and Western Pacific region.
Report of the third meeting of the Scientific Working Group on Bacterial Enteric Infections: Microbiology, Epidemiology, Immunology, and Vaccine Development.
[Unpublished] 1984. 17 p. (WHO/CDD/BEI/84.5)The scientific topic discussed in detail by the Scientific Working Group (SWG) was recent research advances in the field of cholera. The SWG reviewed new knowlenge in areas such as epidemiology and ecology, phage-typing, pathogenesis, immunization, and related pathogens, and made recommendations for future research. The Diarrhoeal Disease Control Pragramme was continuing to emphasize the implementation of oral rehydration therapy as a means of reducing diarrheal mortality, and research aimed at an improved case-management strategy. The Steering Committee granted support to a number of projects aimed at clarifying the epidemiology of diarrhea and the pathogenesis of bacterial agents of acute diarrhea. Support was provided by the Steering Committee to projects aimed at, or closely related to the development of new vaccines against typhoid fever, cholera, and Shigella dysentery.
International Workshop on Youth Participation in Population, Environment, Development at Colombo, 28th Nov. 83 to 2nd Dec. 83.
Maribo, Denmark, WAY, . 120 p.The objectives of the International Youth Workshop on Population and Development were to provide a forum to the leaders of national youth councils and socio-political youth organizations. These leaders were brought together to review national and local youth activities and their plans and action programs for the future. The outlook for these discussions was local, regional, and global. In addition the Workshop aimed at providing interaction among the youth organizations of the developing and the developed countries. These proceedings include an inaugural address by Gemini Atukorata, Minister of Youth Affairs, Government of Sri Lanka and presentations focusing on the following: youth and development; the key role of youth in production and reproduction -- important factors of development; 60% of the aid goes back to the giving country in several ways; adolescent fertility as a major concern; social development for the poor with particular reference to the well-being of children and women; commitment for the cause is the key to attract funds; and observance of the International Youth Year under the themes of participation, development, and peace. The 11th workshop session dealt with follow-up and the future direction of the World Assembly of Youth (WAY). The following points emerged in this most important session: WAY should emphasize "Youth Participation in Development" as the major program; WAY's population programs should not be limited to just information, education, and communication, and youth groups should be encouraged to become service delivery agents for contraceptives wherever possible; environment awareness should become an integral part of population and development programs; youth in the service of children, health for all, and drug abuse should be the new areas of operation for WAY; and programs of youth working in the service of disabled, especially disabled young people, and youth and crime prevention programs also found favor with the participants. Recommendations and action programs are outlined. Proceedings include a summary of WAY activities and resolutions.
[Unpublished] 1984. 51 p.This listing of research projects funded since 1980 by WHO's Diarrhoeal Diseases Control Programme, is arranged by project title, investigator and annual budget allocations. Project titles are listed by Scientific Working Grouping (SWG) and include research on bacterial enteric infections; parasitic diarrheas; viral diarrheas; drug development and management of acute diarrheas; global and regional groups and research strengthening activities. SWG projects are furthermore divided by geographical region: African, American, Eastern Medierranean, European, Southeast Asian and Western Pacific. The priority area for research within each SWG is specified.
Report of the First Meeting of the Scientific Working Group on Bacterial Enteric Infections: Microbiology, Epidemiology, Immunology, and Vaccine Development, Geneva, April 1980.
Geneva, Switzerland, WHO, 1980. 17 p.The group developed a five year research plan (1980-84). Topics were given priority based on the following group-established criteria: 1) the extent of the problem to be studied; 2) the chance of its early success given the limited funds available; and 3) the availability of good research workers with an interest in the problem. The epidemiology and microbiology of Vibrio cholerae 01 and Enterotoxigenic Escherichia coli (ETEC) are given first priority for study, as are immunology and vaccine development against cholera and ETEC diarrhoea. The immunology study will involve: 1) identification of protective antigens, 2) tests for antibody measurement and 3) measurement of acquired immunity. Methods of stimulating mucosal immunity are given first priority, as is the testing of existing candidate cholera vaccines such as B-subunit cholera vaccine and living vaccines made from non-toxigenic V. cholerae. Other organisms which will be studied are Campylobaster jejuni (which can account for up to 15% of acute diarrhoea cases in some settings), Salmonella, (including S. typhi), Shigella and Yersinia enterocolitica. Once there is a better understanding of the modes of transmission of the bacterial enteric pathogens, a study of specific cost effective methods of interrupting their transmission through environmental intervention is suggested, with emphasis on modifications in water supply and water usage, defecation practices, and personal and domestic hygiene. Identification of institutions to undertake research, and funding distribution, were also considered.
Diagnosis and management of febrile children using the WHO / UNICEF guidelines for IMCI in Dhaka, Bangladesh.
Bulletin of the World Health Organization. 2001; 79(12):1096-105.In Dhaka, Bangladesh, a study was conducted to determine the effectiveness of WHO’s integrated management of childhood illnesses (IMCI) guidelines in identifying children with bacterial infections in need of antibiotics. A systematic sample of 669 sick children aged 2-59 months was enrolled in the study. Weight, tactile, measured temperature, and respiratory rate were obtained from each patient. The study revealed that had IMCI guidelines been used to evaluate the subjects, 78% of those with bacterial infections would have received antibiotics, including the majority of children with meningitis (100%), pneumonia (95%), otitis media (95%), urinary tract infection (83%), bacteremia (50%), dysentery (48%), and skin infections (30%). It was also noted that the fever module identified only one additional case of meningitis. Children with bacteraemia were more likely to be febrile, feel hot and have history of fever than those with dysentery and skin infections. Fever combined with parental perception of fast breathing provided a more sensitive fever module for the detection of bacteraemia than the current ICMI module. In an area of low malaria prevalence, the IMCI guidelines provide antibiotics to the majority of children with bacterial infections, but improvements in the fever module are possible.
A rebuttal: Epidemic and endemic meningococcal meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine.
Pediatric Infectious Disease Journal. 2000 Oct; 19(10):945-53.The WHO strategy of instituting mass vaccination to combat meningococcal meningitis in sub-Saharan Africa has failed to control huge epidemics in 1996 and 1997. At best, it would only prevent 50% of cases during the epidemic even under optimal conditions of detection and mobilization of personnel and resources. It also ignores the endemic prevalence of disease that would be categorized as epidemic in other parts of the world. In this respect, this paper attempts to change the recommendation of the WHO for group A meningococcal meningitis. It recommends mass vaccination followed by routine vaccination and offers an agenda for the introduction of conjugate vaccines. Routine immunization with group A meningococcal polysaccharide has been noted to be effective. This approach serves as a means for rational development and field testing of the infrastructure for the deployment of a conjugate vaccine. The addition of meningococcal polysaccharide vaccines to routine immunization in African countries is recommended.